We are live on
!
Find out more
VA
VR Adviser Portfolio holdings
AUM
$2.68B
1-Year Est. Return
422.73%
This Fund
S&P 500
This Quarter
Est. Return
+80.92%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$2.1B
AUM Growth
+$644M
(+44%)
Cap. Flow
-$42.2M
Cap. Flow
% of AUM
-2.01%
Top 10 Holdings %
Top 10 Hldgs %
63.64%
Holding
44
New
8
Increased
15
Reduced
6
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ocular Therapeutix
OCUL
|
+$35.4M |
| 2 |
enGene Therapeutics
ENGN
|
+$31.4M |
| 3 |
Edgewise Therapeutics
EWTX
|
+$28.9M |
| 4 |
KALV
KalVista Pharmaceuticals
KALV
|
+$28.8M |
| 5 |
Dianthus Therapeutics
DNTH
|
+$25.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
+$251M |
| 2 |
AMAM
Ambrx Biopharma Inc
AMAM
|
+$29.5M |
| 3 |
Rhythm Pharmaceuticals
RYTM
|
+$22.8M |
| 4 |
Cabaletta Bio
CABA
|
+$21.5M |
| 5 |
Savara
SVRA
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ADVM
26
DELISTED
Adverum Biotechnologies
ADVM
| $22M | 1.05% |
1,556,419
+1,041,664
| +202% | +$15.8M |
|
27
Celcuity
CELC
$4.21B
| $21M | 1% |
970,000
-915,538
| -49% | -$14.6M |
|
|
ABVX
28
Abivax
ABVX
$10.9B
| $19.2M | 0.92% |
1,345,780
+347,210
| +35% | +$4.48M |
|
29
Immatics
IMTX
$1.18B
| $18.4M | 0.87% |
+1,750,000
| New | +$20.4M |
|
|
LYRA
30
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $16M | 0.76% |
51,522
+10
| +0% | +$2.66K |
|
31
CG Oncology
CGON
$6.28B
| $15.4M | 0.73% |
+350,000
| New | +$14.3M |
|
32
Century Therapeutics
IPSC
$364M
| $14.2M | 0.68% |
+3,405,133
| New | +$14.4M |
|
33
Trevi Therapeutics
TRVI
$2.59B
| $11.8M | 0.56% |
3,422,675
+278
| +0% | +$620 |
|
34
Tenaya Therapeutics
TNYA
$161M
| $8.14M | 0.39% |
+1,555,556
| New | +$7.44M |
|
35
Mineralys Therapeutics
MLYS
$2.25B
| $7.17M | 0.34% |
+555,554
| New | +$6.86M |
|
|
SLRN
36
DELISTED
ACELYRIN
SLRN
| $6.33M | 0.3% |
937,113
| – | – |
|
37
EyePoint Inc
EYPT
$1.03B
| $5.17M | 0.25% |
250,000
| – | – |
|
38
Olema Pharmaceuticals
OLMA
$1B
| $872K | 0.04% |
77,042
| – | – |
|
39
GH Research
GHRS
$1.93B
| – | – |
-1,318,327
| Closed | -$7.65M |
|
40
Milestone Pharmaceuticals
MIST
$138M
| – | – |
-925,048
| Closed | -$1.54M |
|
|
41
Rhythm Pharmaceuticals
RYTM
$6.81B
| – | – |
-495,983
| Closed | -$22.8M |
|
|
42
Savara
SVRA
$1.12B
| – | – |
-3,500,000
| Closed | -$16.4M |
|
|
AMAM
43
DELISTED
Ambrx Biopharma Inc
AMAM
| – | – |
-2,070,000
| Closed | -$29.5M |
|
|
RYZB
44
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| – | – |
-4,030,471
| Closed | -$251M |
|
Similar funds
MMEA
WGI
TCAM
SFI
HC
CI
PCA
LP
VR Adviser's Q1 2024 Portfolio in Review
As of Q1 2024, VR Adviser held 44 positions worth $2.1B, up 44% from $1.46B the previous quarter. Its ten largest holdings account for 64% of the portfolio.
VR Adviser's Q1 2024 filing shows 8 new, 15 increased, 6 reduced and 6 closed positions. Its largest new stake was enGene Therapeutics: 2,565,841 shares worth $43.5M. The largest sale was RayzeBio, Inc. Common Stock, an estimated $251M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- VR Adviser's largest Q1 2024 buy was enGene Therapeutics: 2,565,841 shares worth $43.5M.
- VR Adviser added most to Ocular Therapeutix in Q1 2024, an estimated $35.4M increase.
- VR Adviser's biggest Q1 2024 reduction was Cabaletta Bio, cutting an estimated $21.5M.
- VR Adviser fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $251M.
- VR Adviser's ten largest holdings make up 64% of its $2.1B portfolio in Q1 2024.
- VR Adviser opened 8 new positions and closed 6 in Q1 2024.
- VR Adviser's portfolio value rose 44% quarter-over-quarter to $2.1B.
Based on VR Adviser's 13F filing for Q1 2024, filed 15 May 2024.